Samsung Biologics PolyPeptide Tender Offer Prospectus Set to Publish by End of August, 20 Trading Day Offer Period
Samsung Biologics' $1.8 billion (CHF 1.46 billion) all-cash tender offer for Swiss peptide CDMO PolyPeptide Group (SIX: PPGN) is scheduled to publish the formal offer prospectus by the end of August 2026, following the mandatory 10 trading-day cooling-off period under Swiss takeover law. Terms: CHF 44.31 per share (40% premium to the CHF 31.65 undisturbed price on April 10, 2026). The offer will run for a minimum of 20 trading days on SIX Swiss Exchange and is conditioned on at least 66⅔% of shares tendered on a fully diluted basis plus customary regulatory approvals. Deal close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide. The transaction would give Samsung Biologics one of the top three peptide CDMO capacity positions globally, integrated with Samsung's existing multi-modality biologics network across the U.S., Europe, and India.